ALLMedicine™ Parkinson Disease Center
Research & Reviews 3,667 results
https://clinicaltrials.gov/ct2/show/NCT01496599
May 20th, 2022 - Objectives: The purpose of this protocol is to evaluate possible imaging biomarkers for diagnosis and assessment of disease progression in Parkinson disease (PD) through multi-modal neuroimaging studies. The study will have two parts: Part 1: Comp...
https://clinicaltrials.gov/ct2/show/NCT00001215
May 20th, 2022 - There is a vast spectrum of clinical manifestations encountered in individuals with lysosomal storage diseases. Lysosomal storage disorders occur when an enzyme necessary for breaking down intracellular fats, proteins, recycled products and organe...
https://clinicaltrials.gov/ct2/show/NCT04058457
May 19th, 2022 - A continuous cohort of Parkinson disease patients planned to undergo STN-DBS will be approached to participate in this study (i.e. every patient will be offered participation in the study). Over the same time period other DBS patients (GPi and VIM...
https://clinicaltrials.gov/ct2/show/NCT04778852
May 18th, 2022 - Full Title: QUANTITATIVE ASSESSMENT OF TRAINING EFFECTS USING A WEARABLE EXOSKELETON IN PARKINSON DISEASE PATIENTS RESEARCH PLAN Specific Aims The ability to walk independently is a primary goal when rehabilitating an individual with Parkinson Dis...
https://doi.org/10.1097/WNF.0000000000000501
Clinical Neuropharmacology; Suzuki K, Funakoshi K et. al.
May 18th, 2022 - We hypothesized that rotigotine may have a positive effect on cognitive function in patients with Parkinson disease (PD) by improving daytime motor function and sleep status. Fifteen PD patients with sleep disturbances, defined as a PD Sleep Scale...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046970
Physical Therapy; Osborne JA, Botkin R et. al.
Dec 29th, 2021 - A clinical practice guideline on Parkinson disease was developed by an American Physical Therapy Association volunteer guideline development group that consisted of physical therapists and a neurologist. The guideline was based on systematic revie...
Drugs 7 results see all →
Clinicaltrials.gov 139 results
https://clinicaltrials.gov/ct2/show/NCT01496599
May 20th, 2022 - Objectives: The purpose of this protocol is to evaluate possible imaging biomarkers for diagnosis and assessment of disease progression in Parkinson disease (PD) through multi-modal neuroimaging studies. The study will have two parts: Part 1: Comp...
https://clinicaltrials.gov/ct2/show/NCT00001215
May 20th, 2022 - There is a vast spectrum of clinical manifestations encountered in individuals with lysosomal storage diseases. Lysosomal storage disorders occur when an enzyme necessary for breaking down intracellular fats, proteins, recycled products and organe...
https://clinicaltrials.gov/ct2/show/NCT04058457
May 19th, 2022 - A continuous cohort of Parkinson disease patients planned to undergo STN-DBS will be approached to participate in this study (i.e. every patient will be offered participation in the study). Over the same time period other DBS patients (GPi and VIM...
https://clinicaltrials.gov/ct2/show/NCT04778852
May 18th, 2022 - Full Title: QUANTITATIVE ASSESSMENT OF TRAINING EFFECTS USING A WEARABLE EXOSKELETON IN PARKINSON DISEASE PATIENTS RESEARCH PLAN Specific Aims The ability to walk independently is a primary goal when rehabilitating an individual with Parkinson Dis...
https://clinicaltrials.gov/ct2/show/NCT05222386
May 6th, 2022 - Investigators propose to conduct a pragmatic stepped-wedge comparative effectiveness trial comparing a novel model of providing community-based palliative care for persons living with Parkinson's disease (PD), Lewy Body Dementia (LBD) and related ...
News 207 results
https://www.medpagetoday.com/psychiatry/dementia/97725
Mar 17th, 2022 - Treatment with lithium may be protective against dementia and its subtypes, a retrospective cohort study indicated. Among patients receiving mental health care, those exposed to lithium at standard clinical dosages had a 44% lower risk of receivin...
https://www.mdedge.com/rheumatology/article/252183/rheumatoid-arthritis/dmards-or-corticosteroids-use-may-not-explain
Feb 24th, 2022 - Key clinical point: The use of disease-modifying antirheumatic drugs (DMARD) or corticosteroids did not affect the risk for Parkinson's disease (PD) in patients with rheumatoid arthritis (RA), except for chloroquine/hydroxychloroquine, which may b.
https://www.medscape.com/viewarticle/736108
Jan 21st, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...
https://www.medscape.com/viewarticle/959036
Sep 19th, 2021 - A majority of patients with Parkinson disease (PD) experiencing "off" episodes successfully tolerated titration to an effective and tolerable dose of sublingual apomorphine film (SL-apo; Kynmobi, Sunovion Pharmaceuticals) without the use of antie...
https://www.medpagetoday.com/neurology/parkinsonsdisease/94508
Sep 14th, 2021 - Treatment with the urate precursor inosine did not result in a significant difference in the rate of clinical disease progression in early Parkinson's disease, the phase III SURE-PD3 trial showed. Clinical progression rates, measured by the Moveme...
